{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:30:00Z","timestamp":1787646600514,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Epidermolysis bullosa (EB) is a heterogeneous group of inherited disorders characterised by skin fragility, caused by pathogenic variants in genes encoding structural components of the dermo-epidermal junction. With the advent of next-generation sequencing (NGS), the diagnostic paradigm has shifted from a morphological to a genotype-oriented approach. This review summarises the genetic architecture of EB, the types of mutations and genotype\u2013phenotype relationships, the challenges in interpreting variants of unknown significance (VUS), and therapeutic strategies targeting specific mutational mechanisms, including read-through approaches, exon skipping and genome editing. The role of modifier genes and epigenetic factors in clinical variability is also discussed. The focus is on the translational potential of genomics for personalized therapy in EB. Overall, this review synthesizes the molecular basis of all four major EB types across 16+ classical genes, highlights the paradigm shift where NGS achieves a diagnostic yield exceeding 90%, and critically assesses recent therapeutic milestones\u2014ranging from the first FDA-approved topical gene therapy to precision RNA and genome-editing modalities.<\/jats:p>","DOI":"10.3390\/ijms27177591","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:00:48Z","timestamp":1787644848000},"page":"7591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From the Microscope to the Genome: A New Era in the Molecular Genetics of Epidermolysis Bullosa"],"prefix":"10.3390","volume":"27","author":[{"given":"Maria","family":"Tsvetkova","sequence":"first","affiliation":[{"name":"Department of Biology, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-7155","authenticated-orcid":false,"given":"Tsonka","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Yaneva","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jid.2016.02.819","article-title":"The molecular revolution in cutaneous biology: Era of molecular diagnostics for inherited skin diseases","volume":"137","author":"McGrath","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jdv.19938","article-title":"Evolution of genome diagnostics in epidermolysis bullosa: Unveiling the power of next-generation sequencing","volume":"39","author":"Baardman","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"King, A.D., Deirawan, H., Klein, P.A., Dasgeb, B., Dumur, C.I., and Mehregan, D.R. (2023). Next-generation sequencing in dermatology. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1218404"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of epidermolysis bullosa and future directions: A review","volume":"14","author":"Danescu","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s13555-021-00561-5","article-title":"Clinical perspectives of gene-targeted therapies for epidermolysis bullosa","volume":"11","author":"Welponer","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.pmbts.2020.12.007","article-title":"Advances in gene editing strategies for epidermolysis bullosa","volume":"182","author":"Kocher","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.70251\/HYJR2348.35103111","article-title":"CRISPR-based gene editing therapy for epidermolysis bullosa simplex: Molecular targets and therapeutic strategies","volume":"3","author":"Mirghasemi","year":"2025","journal-title":"Am. J. Stud. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vermeer, F.C., Bremer, J., Sietsma, R.J., Sandilands, A., Hickerson, R.P., Bolling, M.C., Pasmooij, A.M., Lemmink, H.H., Swertz, M.A., and Knoers, N.V. (2021). Therapeutic prospects of exon skipping for epidermolysis bullosa. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212222"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nystr\u00f6m, A., Bruckner-Tuderman, L., and Kiritsi, D. (2021). Dystrophic epidermolysis bullosa: Secondary disease mechanisms and disease modifiers. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.737272"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMsr1406261","article-title":"ClinGen\u2014The Clinical Genome Resource","volume":"372","author":"Rehm","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bischof, J., Hierl, M., and Koller, U. (2024). Emerging gene therapeutics for epidermolysis bullosa under development. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042243"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2391452","DOI":"10.1080\/09546634.2024.2391452","article-title":"Emerging DNA & RNA editing strategies for the treatment of epidermolysis bullosa","volume":"35","author":"Koller","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.omtm.2023.101134","article-title":"CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of dystrophic epidermolysis bullosa gene therapy (B-VEC)","volume":"387","author":"Guide","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ymthe.2023.06.002","article-title":"Gene therapy shine the spotlight on epidermolysis bullosa, bringing hope to patients","volume":"31","author":"Koller","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ymthe.2023.11.027","article-title":"Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells","volume":"32","author":"Cattaneo","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_21","first-page":"149","article-title":"CRISPR-Cas9 Gene Editing in Pediatric Epidermolysis Bullosa","volume":"4","author":"Zimmer","year":"2024","journal-title":"Am. J. Clin. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s13555-024-01239-4","article-title":"Highlights of gene and cell therapy for epidermolysis bullosa and ichthyosis","volume":"14","author":"Koutsoukos","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Guo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eaas9668","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.xjidi.2022.100096","article-title":"Detrimental effects of IFN-\u03b3 on an epidermolysis bullosa simplex cell model and protection by a humanized anti-IFN-\u03b3 monoclonal antibody","volume":"2","author":"Badowski","year":"2022","journal-title":"JID Innov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Meyer-Mueller, C., Osborn, M.J., Tolar, J., Boull, C., and Ebens, C.L. (2022). Revertant mosaicism in epidermolysis bullosa. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010114"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/humu.24331","article-title":"Detection of revertant mosaicism in epidermolysis bullosa through Cas9-targeted long-read sequencing","volume":"43","author":"Natsuga","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/bjd.17943","article-title":"Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa","volume":"181","author":"Twaroski","year":"2019","journal-title":"Br. J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:02:48Z","timestamp":1787644968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":28,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177591"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177591","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}